Endometriosis is a chronic systemic disease: clinical challenges and novel innovations.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review of mechanisms and therapeutic strategies without systematic search or meta-analysis.
PubMed 33640070 · doi:10.1016/S0140-6736(21)00389-5
What was done
This narrative review summarizes clinical challenges, emerging pathophysiology, and therapeutic innovations in endometriosis, specifically assessing evidence for regarding it as a chronic systemic disease rather than an isolated pelvic gynecological condition.
What was found
The authors note that endometriosis affects 5–10% of reproductive-age women globally. Progestins and low-dose oral contraceptives fail in approximately one-third of symptomatic patients, likely attributable to progesterone resistance. The condition is characterized by systemic inflammation, metabolic alterations in liver and adipose tissue, and altered gene expression in the brain contributing to central pain sensitization and mood disorders. Oral gonadotropin-releasing hormone (GnRH) antagonists are identified as an effective and tolerable treatment option when first-line therapies fail. Specific statistical metrics beyond prevalence and treatment failure estimates were not reported in the abstract.
Why it matters
Framing endometriosis as a systemic disease accounts for its widespread extra-pelvic manifestations and encourages earlier diagnosis and personalized multi-modal care, including newer oral GnRH antagonist regimens.
Limits
As a narrative review, the synthesis lacks systematic screening protocols, risk-of-bias evaluation, and meta-analytic pooling. Specific sample sizes and effect sizes from the reviewed studies are not provided in the abstract.
Cited by
- supports Endometriosis officially affects approximately 10% of women.